nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Conjugated Estrogens—osteoporosis	0.078	0.123	CbGbCtD
Dabrafenib—SLCO1B3—Estradiol—osteoporosis	0.0685	0.108	CbGbCtD
Dabrafenib—SLCO1B1—Conjugated Estrogens—osteoporosis	0.0454	0.0719	CbGbCtD
Dabrafenib—SLC22A8—Conjugated Estrogens—osteoporosis	0.0419	0.0664	CbGbCtD
Dabrafenib—SLCO1B1—Estradiol—osteoporosis	0.0399	0.0631	CbGbCtD
Dabrafenib—SLC22A8—Estradiol—osteoporosis	0.0368	0.0583	CbGbCtD
Dabrafenib—ABCG2—Conjugated Estrogens—osteoporosis	0.0361	0.0571	CbGbCtD
Dabrafenib—ABCG2—Estradiol—osteoporosis	0.0317	0.0502	CbGbCtD
Dabrafenib—SLC22A6—Conjugated Estrogens—osteoporosis	0.0292	0.0462	CbGbCtD
Dabrafenib—CYP2C8—Raloxifene—osteoporosis	0.0271	0.0429	CbGbCtD
Dabrafenib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0262	0.0415	CbGbCtD
Dabrafenib—CYP2C8—Cholecalciferol—osteoporosis	0.0209	0.0331	CbGbCtD
Dabrafenib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0177	0.0281	CbGbCtD
Dabrafenib—CYP2C8—Estradiol—osteoporosis	0.0169	0.0267	CbGbCtD
Dabrafenib—CYP3A4—Estropipate—osteoporosis	0.0165	0.0261	CbGbCtD
Dabrafenib—CYP3A4—Calcitriol—osteoporosis	0.0165	0.0261	CbGbCtD
Dabrafenib—CYP3A4—Ergocalciferol—osteoporosis	0.0132	0.0209	CbGbCtD
Dabrafenib—ABCB1—Conjugated Estrogens—osteoporosis	0.013	0.0206	CbGbCtD
Dabrafenib—ABCB1—Estradiol—osteoporosis	0.0114	0.0181	CbGbCtD
Dabrafenib—CYP3A4—Raloxifene—osteoporosis	0.011	0.0174	CbGbCtD
Dabrafenib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0106	0.0168	CbGbCtD
Dabrafenib—CYP3A4—Cholecalciferol—osteoporosis	0.0085	0.0134	CbGbCtD
Dabrafenib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0078	0.0123	CbGbCtD
Dabrafenib—CYP3A4—Estradiol—osteoporosis	0.00685	0.0108	CbGbCtD
Dabrafenib—Cough—Pamidronate—osteoporosis	0.000207	0.000872	CcSEcCtD
Dabrafenib—Constipation—Calcitriol—osteoporosis	0.000207	0.000872	CcSEcCtD
Dabrafenib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000205	0.000863	CcSEcCtD
Dabrafenib—Hypertension—Pamidronate—osteoporosis	0.000205	0.000863	CcSEcCtD
Dabrafenib—Vision blurred—Zoledronate—osteoporosis	0.000204	0.00086	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Raloxifene—osteoporosis	0.000204	0.00086	CcSEcCtD
Dabrafenib—Diarrhoea—Etidronic acid—osteoporosis	0.000204	0.000859	CcSEcCtD
Dabrafenib—Haematuria—Estradiol—osteoporosis	0.000204	0.000858	CcSEcCtD
Dabrafenib—Abdominal pain—Estropipate—osteoporosis	0.000204	0.000858	CcSEcCtD
Dabrafenib—Body temperature increased—Estropipate—osteoporosis	0.000204	0.000858	CcSEcCtD
Dabrafenib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000203	0.000855	CcSEcCtD
Dabrafenib—Infection—Risedronate—osteoporosis	0.000203	0.000852	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000202	0.000851	CcSEcCtD
Dabrafenib—Arthralgia—Pamidronate—osteoporosis	0.000202	0.000851	CcSEcCtD
Dabrafenib—Myalgia—Pamidronate—osteoporosis	0.000202	0.000851	CcSEcCtD
Dabrafenib—Back pain—Conjugated Estrogens—osteoporosis	0.000202	0.00085	CcSEcCtD
Dabrafenib—Epistaxis—Estradiol—osteoporosis	0.000202	0.000849	CcSEcCtD
Dabrafenib—Body temperature increased—Alendronate—osteoporosis	0.000201	0.000845	CcSEcCtD
Dabrafenib—Abdominal pain—Alendronate—osteoporosis	0.000201	0.000845	CcSEcCtD
Dabrafenib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000201	0.000845	CcSEcCtD
Dabrafenib—Anaemia—Zoledronate—osteoporosis	0.0002	0.000844	CcSEcCtD
Dabrafenib—Nervous system disorder—Risedronate—osteoporosis	0.0002	0.000841	CcSEcCtD
Dabrafenib—Skin disorder—Risedronate—osteoporosis	0.000198	0.000833	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000198	0.000833	CcSEcCtD
Dabrafenib—Abdominal pain—Raloxifene—osteoporosis	0.000198	0.000831	CcSEcCtD
Dabrafenib—Body temperature increased—Raloxifene—osteoporosis	0.000198	0.000831	CcSEcCtD
Dabrafenib—Vision blurred—Conjugated Estrogens—osteoporosis	0.000197	0.000828	CcSEcCtD
Dabrafenib—Abdominal pain—Ibandronate—osteoporosis	0.000196	0.000823	CcSEcCtD
Dabrafenib—Body temperature increased—Ibandronate—osteoporosis	0.000196	0.000823	CcSEcCtD
Dabrafenib—Leukopenia—Zoledronate—osteoporosis	0.000194	0.000817	CcSEcCtD
Dabrafenib—Oedema—Pamidronate—osteoporosis	0.000194	0.000816	CcSEcCtD
Dabrafenib—Haemoglobin—Estradiol—osteoporosis	0.000193	0.000812	CcSEcCtD
Dabrafenib—Infection—Pamidronate—osteoporosis	0.000193	0.00081	CcSEcCtD
Dabrafenib—Haemorrhage—Estradiol—osteoporosis	0.000192	0.000808	CcSEcCtD
Dabrafenib—Abdominal pain—Calcitriol—osteoporosis	0.000191	0.000806	CcSEcCtD
Dabrafenib—Body temperature increased—Calcitriol—osteoporosis	0.000191	0.000806	CcSEcCtD
Dabrafenib—Hypersensitivity—Estropipate—osteoporosis	0.00019	0.0008	CcSEcCtD
Dabrafenib—Nervous system disorder—Pamidronate—osteoporosis	0.00019	0.0008	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pamidronate—osteoporosis	0.00019	0.000799	CcSEcCtD
Dabrafenib—Urinary tract disorder—Estradiol—osteoporosis	0.00019	0.000798	CcSEcCtD
Dabrafenib—Vomiting—Etidronic acid—osteoporosis	0.00019	0.000798	CcSEcCtD
Dabrafenib—Cough—Zoledronate—osteoporosis	0.000189	0.000797	CcSEcCtD
Dabrafenib—Oedema peripheral—Estradiol—osteoporosis	0.000189	0.000796	CcSEcCtD
Dabrafenib—Connective tissue disorder—Estradiol—osteoporosis	0.000189	0.000794	CcSEcCtD
Dabrafenib—Urethral disorder—Estradiol—osteoporosis	0.000188	0.000792	CcSEcCtD
Dabrafenib—Rash—Etidronic acid—osteoporosis	0.000188	0.000791	CcSEcCtD
Dabrafenib—Dermatitis—Etidronic acid—osteoporosis	0.000188	0.000791	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pamidronate—osteoporosis	0.000187	0.000789	CcSEcCtD
Dabrafenib—Hypertension—Zoledronate—osteoporosis	0.000187	0.000788	CcSEcCtD
Dabrafenib—Hypersensitivity—Alendronate—osteoporosis	0.000187	0.000788	CcSEcCtD
Dabrafenib—Headache—Etidronic acid—osteoporosis	0.000187	0.000786	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000186	0.000782	CcSEcCtD
Dabrafenib—Asthenia—Estropipate—osteoporosis	0.000185	0.000779	CcSEcCtD
Dabrafenib—Myalgia—Zoledronate—osteoporosis	0.000185	0.000777	CcSEcCtD
Dabrafenib—Arthralgia—Zoledronate—osteoporosis	0.000185	0.000777	CcSEcCtD
Dabrafenib—Insomnia—Risedronate—osteoporosis	0.000184	0.000776	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000183	0.000772	CcSEcCtD
Dabrafenib—Pruritus—Estropipate—osteoporosis	0.000182	0.000768	CcSEcCtD
Dabrafenib—Asthenia—Alendronate—osteoporosis	0.000182	0.000767	CcSEcCtD
Dabrafenib—Hypersensitivity—Ibandronate—osteoporosis	0.000182	0.000767	CcSEcCtD
Dabrafenib—Cough—Conjugated Estrogens—osteoporosis	0.000182	0.000767	CcSEcCtD
Dabrafenib—Hypotension—Pamidronate—osteoporosis	0.000181	0.000762	CcSEcCtD
Dabrafenib—Dry mouth—Zoledronate—osteoporosis	0.000181	0.00076	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000181	0.00076	CcSEcCtD
Dabrafenib—Fatigue—Ethinyl Estradiol—osteoporosis	0.00018	0.000759	CcSEcCtD
Dabrafenib—Pruritus—Alendronate—osteoporosis	0.00018	0.000757	CcSEcCtD
Dabrafenib—Eye disorder—Estradiol—osteoporosis	0.000179	0.000755	CcSEcCtD
Dabrafenib—Constipation—Ethinyl Estradiol—osteoporosis	0.000179	0.000753	CcSEcCtD
Dabrafenib—Hypersensitivity—Calcitriol—osteoporosis	0.000178	0.000751	CcSEcCtD
Dabrafenib—Myalgia—Conjugated Estrogens—osteoporosis	0.000178	0.000748	CcSEcCtD
Dabrafenib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000178	0.000748	CcSEcCtD
Dabrafenib—Asthenia—Ibandronate—osteoporosis	0.000177	0.000747	CcSEcCtD
Dabrafenib—Nausea—Etidronic acid—osteoporosis	0.000177	0.000745	CcSEcCtD
Dabrafenib—Oedema—Zoledronate—osteoporosis	0.000177	0.000745	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000177	0.000743	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000177	0.000743	CcSEcCtD
Dabrafenib—Diarrhoea—Estropipate—osteoporosis	0.000176	0.000743	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000176	0.000741	CcSEcCtD
Dabrafenib—Infection—Zoledronate—osteoporosis	0.000176	0.00074	CcSEcCtD
Dabrafenib—Fatigue—Risedronate—osteoporosis	0.000176	0.00074	CcSEcCtD
Dabrafenib—Insomnia—Pamidronate—osteoporosis	0.000175	0.000738	CcSEcCtD
Dabrafenib—Pruritus—Ibandronate—osteoporosis	0.000175	0.000737	CcSEcCtD
Dabrafenib—Constipation—Risedronate—osteoporosis	0.000174	0.000734	CcSEcCtD
Dabrafenib—Angiopathy—Estradiol—osteoporosis	0.000174	0.000733	CcSEcCtD
Dabrafenib—Diarrhoea—Alendronate—osteoporosis	0.000174	0.000732	CcSEcCtD
Dabrafenib—Asthenia—Calcitriol—osteoporosis	0.000174	0.000731	CcSEcCtD
Dabrafenib—Nervous system disorder—Zoledronate—osteoporosis	0.000174	0.000731	CcSEcCtD
Dabrafenib—Immune system disorder—Estradiol—osteoporosis	0.000173	0.00073	CcSEcCtD
Dabrafenib—Thrombocytopenia—Zoledronate—osteoporosis	0.000173	0.00073	CcSEcCtD
Dabrafenib—Mediastinal disorder—Estradiol—osteoporosis	0.000173	0.000728	CcSEcCtD
Dabrafenib—Chills—Estradiol—osteoporosis	0.000172	0.000725	CcSEcCtD
Dabrafenib—Skin disorder—Zoledronate—osteoporosis	0.000172	0.000724	CcSEcCtD
Dabrafenib—Pruritus—Calcitriol—osteoporosis	0.000171	0.000721	CcSEcCtD
Dabrafenib—Hyperhidrosis—Zoledronate—osteoporosis	0.000171	0.00072	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000171	0.00072	CcSEcCtD
Dabrafenib—Diarrhoea—Raloxifene—osteoporosis	0.000171	0.00072	CcSEcCtD
Dabrafenib—Dizziness—Estropipate—osteoporosis	0.000171	0.000718	CcSEcCtD
Dabrafenib—Oedema—Conjugated Estrogens—osteoporosis	0.00017	0.000717	CcSEcCtD
Dabrafenib—Alopecia—Estradiol—osteoporosis	0.00017	0.000714	CcSEcCtD
Dabrafenib—Infection—Conjugated Estrogens—osteoporosis	0.000169	0.000713	CcSEcCtD
Dabrafenib—Diarrhoea—Ibandronate—osteoporosis	0.000169	0.000712	CcSEcCtD
Dabrafenib—Decreased appetite—Pamidronate—osteoporosis	0.000168	0.000709	CcSEcCtD
Dabrafenib—Mental disorder—Estradiol—osteoporosis	0.000168	0.000708	CcSEcCtD
Dabrafenib—Dizziness—Alendronate—osteoporosis	0.000168	0.000707	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000167	0.000704	CcSEcCtD
Dabrafenib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000167	0.000704	CcSEcCtD
Dabrafenib—Malnutrition—Estradiol—osteoporosis	0.000167	0.000704	CcSEcCtD
Dabrafenib—Erythema—Estradiol—osteoporosis	0.000167	0.000704	CcSEcCtD
Dabrafenib—Fatigue—Pamidronate—osteoporosis	0.000167	0.000703	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Risedronate—osteoporosis	0.000167	0.000702	CcSEcCtD
Dabrafenib—Constipation—Pamidronate—osteoporosis	0.000166	0.000698	CcSEcCtD
Dabrafenib—Diarrhoea—Calcitriol—osteoporosis	0.000166	0.000697	CcSEcCtD
Dabrafenib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000166	0.000697	CcSEcCtD
Dabrafenib—Hypotension—Zoledronate—osteoporosis	0.000165	0.000696	CcSEcCtD
Dabrafenib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000165	0.000696	CcSEcCtD
Dabrafenib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000165	0.000696	CcSEcCtD
Dabrafenib—Dizziness—Raloxifene—osteoporosis	0.000165	0.000695	CcSEcCtD
Dabrafenib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000165	0.000694	CcSEcCtD
Dabrafenib—Vomiting—Estropipate—osteoporosis	0.000164	0.00069	CcSEcCtD
Dabrafenib—Dizziness—Ibandronate—osteoporosis	0.000164	0.000689	CcSEcCtD
Dabrafenib—Rash—Estropipate—osteoporosis	0.000163	0.000685	CcSEcCtD
Dabrafenib—Dermatitis—Estropipate—osteoporosis	0.000162	0.000684	CcSEcCtD
Dabrafenib—Back pain—Estradiol—osteoporosis	0.000162	0.000681	CcSEcCtD
Dabrafenib—Headache—Estropipate—osteoporosis	0.000162	0.00068	CcSEcCtD
Dabrafenib—Vomiting—Alendronate—osteoporosis	0.000162	0.00068	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000161	0.000679	CcSEcCtD
Dabrafenib—Abdominal pain—Risedronate—osteoporosis	0.000161	0.000678	CcSEcCtD
Dabrafenib—Body temperature increased—Risedronate—osteoporosis	0.000161	0.000678	CcSEcCtD
Dabrafenib—Muscle spasms—Estradiol—osteoporosis	0.000161	0.000676	CcSEcCtD
Dabrafenib—Rash—Alendronate—osteoporosis	0.00016	0.000674	CcSEcCtD
Dabrafenib—Insomnia—Zoledronate—osteoporosis	0.00016	0.000674	CcSEcCtD
Dabrafenib—Dermatitis—Alendronate—osteoporosis	0.00016	0.000674	CcSEcCtD
Dabrafenib—Hypotension—Conjugated Estrogens—osteoporosis	0.000159	0.00067	CcSEcCtD
Dabrafenib—Headache—Alendronate—osteoporosis	0.000159	0.00067	CcSEcCtD
Dabrafenib—Vomiting—Raloxifene—osteoporosis	0.000159	0.000669	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000158	0.000667	CcSEcCtD
Dabrafenib—Rash—Raloxifene—osteoporosis	0.000158	0.000663	CcSEcCtD
Dabrafenib—Dermatitis—Raloxifene—osteoporosis	0.000157	0.000663	CcSEcCtD
Dabrafenib—Vomiting—Ibandronate—osteoporosis	0.000157	0.000662	CcSEcCtD
Dabrafenib—Headache—Raloxifene—osteoporosis	0.000157	0.000659	CcSEcCtD
Dabrafenib—Rash—Ibandronate—osteoporosis	0.000156	0.000656	CcSEcCtD
Dabrafenib—Dermatitis—Ibandronate—osteoporosis	0.000156	0.000656	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000155	0.000654	CcSEcCtD
Dabrafenib—Headache—Ibandronate—osteoporosis	0.000155	0.000652	CcSEcCtD
Dabrafenib—Insomnia—Conjugated Estrogens—osteoporosis	0.000154	0.000649	CcSEcCtD
Dabrafenib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000154	0.000648	CcSEcCtD
Dabrafenib—Vomiting—Calcitriol—osteoporosis	0.000154	0.000648	CcSEcCtD
Dabrafenib—Decreased appetite—Zoledronate—osteoporosis	0.000154	0.000648	CcSEcCtD
Dabrafenib—Nausea—Estropipate—osteoporosis	0.000153	0.000645	CcSEcCtD
Dabrafenib—Abdominal pain—Pamidronate—osteoporosis	0.000153	0.000645	CcSEcCtD
Dabrafenib—Body temperature increased—Pamidronate—osteoporosis	0.000153	0.000645	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000153	0.000643	CcSEcCtD
Dabrafenib—Rash—Calcitriol—osteoporosis	0.000153	0.000643	CcSEcCtD
Dabrafenib—Fatigue—Zoledronate—osteoporosis	0.000153	0.000642	CcSEcCtD
Dabrafenib—Dermatitis—Calcitriol—osteoporosis	0.000153	0.000642	CcSEcCtD
Dabrafenib—Headache—Calcitriol—osteoporosis	0.000152	0.000639	CcSEcCtD
Dabrafenib—Constipation—Zoledronate—osteoporosis	0.000151	0.000637	CcSEcCtD
Dabrafenib—Nausea—Alendronate—osteoporosis	0.000151	0.000635	CcSEcCtD
Dabrafenib—Hypersensitivity—Risedronate—osteoporosis	0.00015	0.000632	CcSEcCtD
Dabrafenib—Asthenia—Ethinyl Estradiol—osteoporosis	0.00015	0.000631	CcSEcCtD
Dabrafenib—Nausea—Raloxifene—osteoporosis	0.000148	0.000625	CcSEcCtD
Dabrafenib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000148	0.000624	CcSEcCtD
Dabrafenib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000148	0.000623	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000147	0.000619	CcSEcCtD
Dabrafenib—Fatigue—Conjugated Estrogens—osteoporosis	0.000147	0.000619	CcSEcCtD
Dabrafenib—Nausea—Ibandronate—osteoporosis	0.000147	0.000618	CcSEcCtD
Dabrafenib—Asthenia—Risedronate—osteoporosis	0.000146	0.000616	CcSEcCtD
Dabrafenib—Cough—Estradiol—osteoporosis	0.000146	0.000614	CcSEcCtD
Dabrafenib—Constipation—Conjugated Estrogens—osteoporosis	0.000146	0.000614	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000145	0.000609	CcSEcCtD
Dabrafenib—Hypertension—Estradiol—osteoporosis	0.000144	0.000607	CcSEcCtD
Dabrafenib—Pruritus—Risedronate—osteoporosis	0.000144	0.000607	CcSEcCtD
Dabrafenib—Nausea—Calcitriol—osteoporosis	0.000144	0.000605	CcSEcCtD
Dabrafenib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000143	0.000602	CcSEcCtD
Dabrafenib—Hypersensitivity—Pamidronate—osteoporosis	0.000143	0.000601	CcSEcCtD
Dabrafenib—Arthralgia—Estradiol—osteoporosis	0.000142	0.000599	CcSEcCtD
Dabrafenib—Myalgia—Estradiol—osteoporosis	0.000142	0.000599	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000141	0.000595	CcSEcCtD
Dabrafenib—Abdominal pain—Zoledronate—osteoporosis	0.00014	0.000589	CcSEcCtD
Dabrafenib—Body temperature increased—Zoledronate—osteoporosis	0.00014	0.000589	CcSEcCtD
Dabrafenib—Diarrhoea—Risedronate—osteoporosis	0.000139	0.000587	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000139	0.000587	CcSEcCtD
Dabrafenib—Dry mouth—Estradiol—osteoporosis	0.000139	0.000586	CcSEcCtD
Dabrafenib—Asthenia—Pamidronate—osteoporosis	0.000139	0.000585	CcSEcCtD
Dabrafenib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000138	0.000582	CcSEcCtD
Dabrafenib—Pruritus—Pamidronate—osteoporosis	0.000137	0.000577	CcSEcCtD
Dabrafenib—Oedema—Estradiol—osteoporosis	0.000136	0.000574	CcSEcCtD
Dabrafenib—Infection—Estradiol—osteoporosis	0.000136	0.00057	CcSEcCtD
Dabrafenib—Dizziness—Risedronate—osteoporosis	0.000135	0.000567	CcSEcCtD
Dabrafenib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000135	0.000567	CcSEcCtD
Dabrafenib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000135	0.000567	CcSEcCtD
Dabrafenib—Nervous system disorder—Estradiol—osteoporosis	0.000134	0.000563	CcSEcCtD
Dabrafenib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000133	0.00056	CcSEcCtD
Dabrafenib—Diarrhoea—Pamidronate—osteoporosis	0.000133	0.000558	CcSEcCtD
Dabrafenib—Skin disorder—Estradiol—osteoporosis	0.000132	0.000558	CcSEcCtD
Dabrafenib—Hyperhidrosis—Estradiol—osteoporosis	0.000132	0.000555	CcSEcCtD
Dabrafenib—Rash—Ethinyl Estradiol—osteoporosis	0.000132	0.000555	CcSEcCtD
Dabrafenib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000132	0.000554	CcSEcCtD
Dabrafenib—Headache—Ethinyl Estradiol—osteoporosis	0.000131	0.000551	CcSEcCtD
Dabrafenib—Hypersensitivity—Zoledronate—osteoporosis	0.00013	0.000549	CcSEcCtD
Dabrafenib—Vomiting—Risedronate—osteoporosis	0.00013	0.000546	CcSEcCtD
Dabrafenib—Rash—Risedronate—osteoporosis	0.000129	0.000541	CcSEcCtD
Dabrafenib—Dermatitis—Risedronate—osteoporosis	0.000128	0.000541	CcSEcCtD
Dabrafenib—Dizziness—Pamidronate—osteoporosis	0.000128	0.000539	CcSEcCtD
Dabrafenib—Headache—Risedronate—osteoporosis	0.000128	0.000538	CcSEcCtD
Dabrafenib—Asthenia—Zoledronate—osteoporosis	0.000127	0.000535	CcSEcCtD
Dabrafenib—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000126	0.000529	CcSEcCtD
Dabrafenib—Pruritus—Zoledronate—osteoporosis	0.000125	0.000527	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000124	0.000523	CcSEcCtD
Dabrafenib—Nausea—Ethinyl Estradiol—osteoporosis	0.000124	0.000523	CcSEcCtD
Dabrafenib—Insomnia—Estradiol—osteoporosis	0.000123	0.000519	CcSEcCtD
Dabrafenib—Vomiting—Pamidronate—osteoporosis	0.000123	0.000519	CcSEcCtD
Dabrafenib—Asthenia—Conjugated Estrogens—osteoporosis	0.000122	0.000515	CcSEcCtD
Dabrafenib—Rash—Pamidronate—osteoporosis	0.000122	0.000514	CcSEcCtD
Dabrafenib—Dermatitis—Pamidronate—osteoporosis	0.000122	0.000514	CcSEcCtD
Dabrafenib—Headache—Pamidronate—osteoporosis	0.000121	0.000511	CcSEcCtD
Dabrafenib—Diarrhoea—Zoledronate—osteoporosis	0.000121	0.00051	CcSEcCtD
Dabrafenib—Nausea—Risedronate—osteoporosis	0.000121	0.00051	CcSEcCtD
Dabrafenib—Pruritus—Conjugated Estrogens—osteoporosis	0.000121	0.000508	CcSEcCtD
Dabrafenib—Decreased appetite—Estradiol—osteoporosis	0.000119	0.000499	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000118	0.000496	CcSEcCtD
Dabrafenib—Fatigue—Estradiol—osteoporosis	0.000118	0.000495	CcSEcCtD
Dabrafenib—Dizziness—Zoledronate—osteoporosis	0.000117	0.000493	CcSEcCtD
Dabrafenib—Constipation—Estradiol—osteoporosis	0.000117	0.000491	CcSEcCtD
Dabrafenib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000117	0.000491	CcSEcCtD
Dabrafenib—Nausea—Pamidronate—osteoporosis	0.000115	0.000485	CcSEcCtD
Dabrafenib—Dizziness—Conjugated Estrogens—osteoporosis	0.000113	0.000474	CcSEcCtD
Dabrafenib—Vomiting—Zoledronate—osteoporosis	0.000113	0.000474	CcSEcCtD
Dabrafenib—Rash—Zoledronate—osteoporosis	0.000112	0.00047	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Estradiol—osteoporosis	0.000112	0.00047	CcSEcCtD
Dabrafenib—Dermatitis—Zoledronate—osteoporosis	0.000112	0.000469	CcSEcCtD
Dabrafenib—Headache—Zoledronate—osteoporosis	0.000111	0.000467	CcSEcCtD
Dabrafenib—Vomiting—Conjugated Estrogens—osteoporosis	0.000108	0.000456	CcSEcCtD
Dabrafenib—Abdominal pain—Estradiol—osteoporosis	0.000108	0.000454	CcSEcCtD
Dabrafenib—Body temperature increased—Estradiol—osteoporosis	0.000108	0.000454	CcSEcCtD
Dabrafenib—Rash—Conjugated Estrogens—osteoporosis	0.000107	0.000452	CcSEcCtD
Dabrafenib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000107	0.000452	CcSEcCtD
Dabrafenib—Headache—Conjugated Estrogens—osteoporosis	0.000107	0.000449	CcSEcCtD
Dabrafenib—Nausea—Zoledronate—osteoporosis	0.000105	0.000443	CcSEcCtD
Dabrafenib—Nausea—Conjugated Estrogens—osteoporosis	0.000101	0.000426	CcSEcCtD
Dabrafenib—Hypersensitivity—Estradiol—osteoporosis	0.000101	0.000423	CcSEcCtD
Dabrafenib—Asthenia—Estradiol—osteoporosis	9.79e-05	0.000412	CcSEcCtD
Dabrafenib—Pruritus—Estradiol—osteoporosis	9.65e-05	0.000406	CcSEcCtD
Dabrafenib—Diarrhoea—Estradiol—osteoporosis	9.33e-05	0.000393	CcSEcCtD
Dabrafenib—Dizziness—Estradiol—osteoporosis	9.02e-05	0.00038	CcSEcCtD
Dabrafenib—Vomiting—Estradiol—osteoporosis	8.67e-05	0.000365	CcSEcCtD
Dabrafenib—Rash—Estradiol—osteoporosis	8.6e-05	0.000362	CcSEcCtD
Dabrafenib—Dermatitis—Estradiol—osteoporosis	8.59e-05	0.000362	CcSEcCtD
Dabrafenib—Headache—Estradiol—osteoporosis	8.55e-05	0.00036	CcSEcCtD
Dabrafenib—Nausea—Estradiol—osteoporosis	8.1e-05	0.000341	CcSEcCtD
Dabrafenib—RAF1—Disease—DKK1—osteoporosis	3.15e-05	0.000242	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TGFB1—osteoporosis	3.14e-05	0.000241	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—IDH2—osteoporosis	3.11e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL1B—osteoporosis	3.11e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—LEP—osteoporosis	3.1e-05	0.000238	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO1—osteoporosis	3.09e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.08e-05	0.000236	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ACP5—osteoporosis	3.08e-05	0.000236	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—WNT1—osteoporosis	3.07e-05	0.000236	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.07e-05	0.000235	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PSMA2—osteoporosis	3.05e-05	0.000234	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PSMA5—osteoporosis	3.05e-05	0.000234	CbGpPWpGaD
Dabrafenib—RAF1—Disease—WNT1—osteoporosis	3.04e-05	0.000233	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.04e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—osteoporosis	3.02e-05	0.000231	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPD2—osteoporosis	3e-05	0.00023	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PGLS—osteoporosis	3e-05	0.00023	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3e-05	0.00023	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGA—osteoporosis	2.99e-05	0.000229	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.99e-05	0.000229	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—osteoporosis	2.97e-05	0.000228	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—osteoporosis	2.96e-05	0.000227	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGA—osteoporosis	2.95e-05	0.000226	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	2.95e-05	0.000226	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL1B—osteoporosis	2.94e-05	0.000225	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—osteoporosis	2.93e-05	0.000225	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP27A1—osteoporosis	2.93e-05	0.000224	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.92e-05	0.000224	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.9e-05	0.000222	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CALCA—osteoporosis	2.87e-05	0.00022	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TPI1—osteoporosis	2.86e-05	0.000219	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ACP5—osteoporosis	2.85e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—osteoporosis	2.84e-05	0.000218	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—osteoporosis	2.82e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—osteoporosis	2.81e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PSMA2—osteoporosis	2.81e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PSMA5—osteoporosis	2.81e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IRS2—osteoporosis	2.8e-05	0.000214	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—osteoporosis	2.8e-05	0.000214	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTHLH—osteoporosis	2.78e-05	0.000213	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—BMP2—osteoporosis	2.78e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TLN1—osteoporosis	2.77e-05	0.000212	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PKM—osteoporosis	2.76e-05	0.000211	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FDPS—osteoporosis	2.76e-05	0.000211	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ATIC—osteoporosis	2.74e-05	0.00021	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PNP—osteoporosis	2.74e-05	0.00021	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGB—osteoporosis	2.72e-05	0.000209	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—P4HB—osteoporosis	2.69e-05	0.000206	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—IRS2—osteoporosis	2.69e-05	0.000206	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.68e-05	0.000206	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TPI1—osteoporosis	2.65e-05	0.000203	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GAPDH—osteoporosis	2.64e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO1—osteoporosis	2.63e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—osteoporosis	2.63e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—osteoporosis	2.63e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—osteoporosis	2.63e-05	0.000202	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PSMA2—osteoporosis	2.63e-05	0.000201	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PSMA5—osteoporosis	2.63e-05	0.000201	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PGLS—osteoporosis	2.61e-05	0.0002	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPD2—osteoporosis	2.61e-05	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—osteoporosis	2.61e-05	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6R—osteoporosis	2.6e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PSMA2—osteoporosis	2.59e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PSMA5—osteoporosis	2.59e-05	0.000199	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—osteoporosis	2.59e-05	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—osteoporosis	2.58e-05	0.000198	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.58e-05	0.000198	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—osteoporosis	2.57e-05	0.000197	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—RAP1A—osteoporosis	2.57e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IGF1—osteoporosis	2.51e-05	0.000193	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—P4HB—osteoporosis	2.49e-05	0.000191	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ADCY5—osteoporosis	2.49e-05	0.000191	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP19A1—osteoporosis	2.47e-05	0.000189	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CALCA—osteoporosis	2.45e-05	0.000188	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GAPDH—osteoporosis	2.44e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IRS1—osteoporosis	2.44e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CALCA—osteoporosis	2.42e-05	0.000185	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ATIC—osteoporosis	2.39e-05	0.000183	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PNP—osteoporosis	2.39e-05	0.000183	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—P4HB—osteoporosis	2.39e-05	0.000183	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—RAP1A—osteoporosis	2.38e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KL—osteoporosis	2.38e-05	0.000182	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—IRS1—osteoporosis	2.35e-05	0.00018	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—OXCT1—osteoporosis	2.33e-05	0.000179	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA2—osteoporosis	2.33e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	2.33e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTH—osteoporosis	2.32e-05	0.000178	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6R—osteoporosis	2.3e-05	0.000176	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—osteoporosis	2.29e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RAP1A—osteoporosis	2.28e-05	0.000175	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MGLL—osteoporosis	2.27e-05	0.000174	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CNR2—osteoporosis	2.26e-05	0.000173	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.25e-05	0.000173	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.24e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFATC1—osteoporosis	2.23e-05	0.000171	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KL—osteoporosis	2.22e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DKK1—osteoporosis	2.21e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KL—osteoporosis	2.2e-05	0.000168	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IRS2—osteoporosis	2.18e-05	0.000167	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.14e-05	0.000164	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—WNT1—osteoporosis	2.13e-05	0.000163	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO1—osteoporosis	2.08e-05	0.000159	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGA—osteoporosis	2.07e-05	0.000159	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PSMA2—osteoporosis	2.05e-05	0.000157	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PSMA5—osteoporosis	2.05e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ADCY5—osteoporosis	2.04e-05	0.000156	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—OXCT1—osteoporosis	2.03e-05	0.000156	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA2—osteoporosis	2.03e-05	0.000156	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADCY5—osteoporosis	2.02e-05	0.000155	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GPX1—osteoporosis	2.01e-05	0.000154	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MGLL—osteoporosis	1.98e-05	0.000152	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—IDH2—osteoporosis	1.93e-05	0.000148	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO1—osteoporosis	1.92e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTHLH—osteoporosis	1.92e-05	0.000147	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BMP2—osteoporosis	1.92e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IRS1—osteoporosis	1.9e-05	0.000146	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PSMA2—osteoporosis	1.9e-05	0.000145	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PSMA5—osteoporosis	1.9e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGB—osteoporosis	1.88e-05	0.000144	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AGER—osteoporosis	1.87e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ADCY5—osteoporosis	1.86e-05	0.000143	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—osteoporosis	1.86e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—osteoporosis	1.82e-05	0.00014	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSMA5—osteoporosis	1.82e-05	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PSMA2—osteoporosis	1.82e-05	0.000139	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP27A1—osteoporosis	1.82e-05	0.000139	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—POMC—osteoporosis	1.8e-05	0.000138	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—osteoporosis	1.79e-05	0.000137	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6R—osteoporosis	1.78e-05	0.000137	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ACP5—osteoporosis	1.77e-05	0.000135	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.74e-05	0.000134	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ADCY5—osteoporosis	1.74e-05	0.000133	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—osteoporosis	1.72e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ADCY5—osteoporosis	1.72e-05	0.000132	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PKM—osteoporosis	1.7e-05	0.00013	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FDPS—osteoporosis	1.7e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALCA—osteoporosis	1.69e-05	0.00013	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—osteoporosis	1.68e-05	0.000129	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—IDH2—osteoporosis	1.68e-05	0.000129	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP19A1—osteoporosis	1.66e-05	0.000127	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPI1—osteoporosis	1.64e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRS2—osteoporosis	1.63e-05	0.000125	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—osteoporosis	1.62e-05	0.000124	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PGLS—osteoporosis	1.61e-05	0.000123	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPD2—osteoporosis	1.61e-05	0.000123	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP27A1—osteoporosis	1.58e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—osteoporosis	1.58e-05	0.000121	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.55e-05	0.000119	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.55e-05	0.000119	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—P4HB—osteoporosis	1.54e-05	0.000118	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ACP5—osteoporosis	1.54e-05	0.000118	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP19A1—osteoporosis	1.54e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KL—osteoporosis	1.54e-05	0.000118	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—osteoporosis	1.54e-05	0.000118	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IRS2—osteoporosis	1.52e-05	0.000117	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GAPDH—osteoporosis	1.52e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—osteoporosis	1.51e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IRS2—osteoporosis	1.5e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—osteoporosis	1.5e-05	0.000115	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LEP—osteoporosis	1.49e-05	0.000114	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—osteoporosis	1.49e-05	0.000114	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—RAP1A—osteoporosis	1.48e-05	0.000113	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ATIC—osteoporosis	1.47e-05	0.000113	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PNP—osteoporosis	1.47e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6R—osteoporosis	1.46e-05	0.000112	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.45e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.45e-05	0.000111	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—osteoporosis	1.43e-05	0.00011	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPI1—osteoporosis	1.43e-05	0.00011	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ESR1—osteoporosis	1.42e-05	0.000109	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRS1—osteoporosis	1.42e-05	0.000109	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADCY5—osteoporosis	1.36e-05	0.000104	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—osteoporosis	1.35e-05	0.000104	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—P4HB—osteoporosis	1.35e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6R—osteoporosis	1.34e-05	0.000102	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IRS1—osteoporosis	1.33e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GAPDH—osteoporosis	1.32e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IRS1—osteoporosis	1.31e-05	0.000101	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.29e-05	9.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—RAP1A—osteoporosis	1.29e-05	9.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—osteoporosis	1.28e-05	9.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADCY5—osteoporosis	1.26e-05	9.63e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—osteoporosis	1.25e-05	9.6e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA2—osteoporosis	1.25e-05	9.59e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—OXCT1—osteoporosis	1.25e-05	9.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6R—osteoporosis	1.25e-05	9.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—osteoporosis	1.25e-05	9.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6R—osteoporosis	1.23e-05	9.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—osteoporosis	1.23e-05	9.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MGLL—osteoporosis	1.22e-05	9.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADCY5—osteoporosis	1.2e-05	9.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO1—osteoporosis	1.19e-05	9.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMA2—osteoporosis	1.18e-05	9.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMA5—osteoporosis	1.18e-05	9.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—osteoporosis	1.17e-05	8.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—osteoporosis	1.16e-05	8.87e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—osteoporosis	1.16e-05	8.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—osteoporosis	1.06e-05	8.1e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—osteoporosis	1.05e-05	8.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS2—osteoporosis	1.05e-05	8.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO1—osteoporosis	1.04e-05	7.97e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH2—osteoporosis	1.04e-05	7.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—osteoporosis	1.03e-05	7.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMA2—osteoporosis	1.02e-05	7.85e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMA5—osteoporosis	1.02e-05	7.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—osteoporosis	1.02e-05	7.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—osteoporosis	1.02e-05	7.79e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—osteoporosis	9.98e-06	7.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ESR1—osteoporosis	9.85e-06	7.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP27A1—osteoporosis	9.75e-06	7.47e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP19A1—osteoporosis	9.54e-06	7.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACP5—osteoporosis	9.49e-06	7.27e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—osteoporosis	9.24e-06	7.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS1—osteoporosis	9.2e-06	7.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—osteoporosis	8.86e-06	6.79e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPI1—osteoporosis	8.82e-06	6.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6R—osteoporosis	8.64e-06	6.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—osteoporosis	8.52e-06	6.53e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP19A1—osteoporosis	8.31e-06	6.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—P4HB—osteoporosis	8.29e-06	6.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GAPDH—osteoporosis	8.14e-06	6.24e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—osteoporosis	7.95e-06	6.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RAP1A—osteoporosis	7.93e-06	6.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADCY5—osteoporosis	7.8e-06	5.98e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—osteoporosis	7.77e-06	5.96e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—osteoporosis	7.4e-06	5.67e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—osteoporosis	7.38e-06	5.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—osteoporosis	7.31e-06	5.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—osteoporosis	7.3e-06	5.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—osteoporosis	7.17e-06	5.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADCY5—osteoporosis	6.79e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—osteoporosis	6.77e-06	5.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—osteoporosis	6.52e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—osteoporosis	6.41e-06	4.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMA5—osteoporosis	6.31e-06	4.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMA2—osteoporosis	6.31e-06	4.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—osteoporosis	6.25e-06	4.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—osteoporosis	5.95e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—osteoporosis	5.74e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—osteoporosis	5.56e-06	4.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—osteoporosis	5.5e-06	4.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.12e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—osteoporosis	5.12e-06	3.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—osteoporosis	5.11e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—osteoporosis	5e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADCY5—osteoporosis	4.19e-06	3.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—osteoporosis	4.17e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—osteoporosis	3.85e-06	2.95e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—osteoporosis	3.85e-06	2.95e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—osteoporosis	3.08e-06	2.36e-05	CbGpPWpGaD
